Catalyst Event
Johnson & Johnson (JNJ) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
3/18/2026, 12:00:00 AM
The U.S. Food and Drug Administration (FDA) is expected to approve Icotyde (icotrokinra) on March 18, 2026, for treating moderate-to-severe plaque psoriasis; analysts forecast the drug to achieve blockbuster sales. High impact estimated due to significant revenue potential forecasted.
Korean Translation
2026년 3월 18일 미국 FDA의 아이코타이드(Icotyde) 승인이 예상됨. 분석가들은 이 약물이 블록버스터급 매출을 달성할 것으로 전망됨.
Related Recent Events
Devon Energy Corp (DVN) · Earnings Release
Market reaction is estimated to be significant as the first report post-merger; Q1 2026 earnings release is scheduled.
5/5/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
First-quarter 2026 financial and operating results are scheduled to be released before the market opens on April 30, 2026. Medium importance estimated as earnings reports typically drive significant price movement, scheduled.
4/30/2026, 12:00:00 AM
Halliburton Co (HAL) · Earnings Release
First quarter 2026 earnings release and conference call scheduled. This scheduling announcement is estimated to have a price impact of 1% or more, scheduled.
4/28/2026, 12:00:00 AM
Chevron Corp (CVX) · Earnings Release
Chevron is scheduled to report its Q1 2026 earnings on April 24, 2026; analysts forecast an EPS of $1.72, scheduled.
4/24/2026, 12:00:00 AM
Comcast Corp (CMCSA) · Earnings Release
First quarter 2026 earnings release and conference call on April 23, 2026, with importance estimated as Low as it is a routine earnings announcement, scheduled.
4/23/2026, 12:00:00 AM
CME Group Inc (CME) · Earnings Release
CME Group is scheduled to announce its earnings for the first quarter of 2026 before the market opens on April 22, 2026; low importance is estimated as the announcement is expected to cause at least a 1% price impact, scheduled.
4/22/2026, 12:00:00 AM